Triple-negative breast cancer: Bridging the gap from cancer genomics to predictive biomarkers

S. Lindsey Davis, S Gail Eckhardt, John J. Tentler, Jennifer R. Diamond

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.

Original languageEnglish (US)
Pages (from-to)88-100
Number of pages13
JournalTherapeutic Advances in Medical Oncology
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Triple Negative Breast Neoplasms
Genomics
Biomarkers
Neoplasms
Therapeutics
Breast Neoplasms
Drug Therapy

Keywords

  • biomarkers
  • targeted therapy
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Triple-negative breast cancer : Bridging the gap from cancer genomics to predictive biomarkers. / Davis, S. Lindsey; Eckhardt, S Gail; Tentler, John J.; Diamond, Jennifer R.

In: Therapeutic Advances in Medical Oncology, Vol. 6, No. 3, 01.01.2014, p. 88-100.

Research output: Contribution to journalReview article

Davis, S. Lindsey ; Eckhardt, S Gail ; Tentler, John J. ; Diamond, Jennifer R. / Triple-negative breast cancer : Bridging the gap from cancer genomics to predictive biomarkers. In: Therapeutic Advances in Medical Oncology. 2014 ; Vol. 6, No. 3. pp. 88-100.
@article{173eeb4b9811483b9e211183a71397d5,
title = "Triple-negative breast cancer: Bridging the gap from cancer genomics to predictive biomarkers",
abstract = "Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.",
keywords = "biomarkers, targeted therapy, triple-negative breast cancer",
author = "Davis, {S. Lindsey} and Eckhardt, {S Gail} and Tentler, {John J.} and Diamond, {Jennifer R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1758834013519843",
language = "English (US)",
volume = "6",
pages = "88--100",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Triple-negative breast cancer

T2 - Bridging the gap from cancer genomics to predictive biomarkers

AU - Davis, S. Lindsey

AU - Eckhardt, S Gail

AU - Tentler, John J.

AU - Diamond, Jennifer R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.

AB - Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.

KW - biomarkers

KW - targeted therapy

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84899010273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899010273&partnerID=8YFLogxK

U2 - 10.1177/1758834013519843

DO - 10.1177/1758834013519843

M3 - Review article

AN - SCOPUS:84899010273

VL - 6

SP - 88

EP - 100

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 3

ER -